$OM
Outset Medical, Inc. Stock $om

$om Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023002648 Filed on February 13, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$33.47M	$32.01M	$115.4M
YoY Change	9.55%	13.69%	12.45%
Cost Of Revenue	$27.04M	$26.73M	$97.54M
YoY Change	3.57%	7.66%	2.68%
Gross Profit	$6.428M	$5.273M	$17.83M
YoY Change	44.71%	58.78%	134.4%
Gross Profit Margin	19.21%	16.47%	15.46%
Selling, General & Admin	$36.12M	$33.65M	$130.0M
YoY Change	20.06%	2.88%	28.22%
% of Gross Profit	561.92%	638.21%	728.97%
Research & Development	$13.79M	$11.44M	$48.86M
YoY Change	27.35%	0.3%	32.97%
% of Gross Profit	214.58%	217.03%	273.96%
Depreciation & Amortization	$1.384M	$1.269M	$5.169M
YoY Change	9.67%	-2.08%	0.14%
% of Gross Profit	21.53%	24.07%	28.99%
Operating Expenses	$49.91M	$45.10M	$178.9M
YoY Change	21.99%	2.21%	29.48%
Operating Profit	-$43.49M	-$39.82M	-$161.0M
YoY Change	19.22%	-2.39%	23.37%
Interest Expense	$2.942M	-$189.0K	$3.566M
YoY Change	597.16%	-38.64%	107.93%
% of Operating Profit
Other Income/Expense, Net	$2.648M	$0.00	$3.291M
YoY Change	2106.67%		560.84%
Pretax Income	-$43.78M	-$41.38M	-$162.7M
YoY Change	19.04%	0.66%	23.47%
Income Tax	$192.0K	$64.00K	$295.0K
% Of Pretax Income
Net Earnings	-$44.00M	-$41.44M	-$163.0M
YoY Change	19.27%	0.51%	23.51%
Net Earnings / Revenue	-131.47%	-129.48%	-141.24%
Basic Earnings Per Share	-$0.90		-$3.38
Diluted Earnings Per Share	-$0.90	-$0.84	-$3.38
COMMON SHARES
Basic Shares Outstanding	48.64M	48.31M	48.16K
Diluted Shares Outstanding	48.78K		48.16K

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$123.8M	$287.5M	$287.5M
YoY Change	-59.04%	-15.31%	-15.31%
Cash & Equivalents	$36.39M	$73.22M	$73.22M
Short-Term Investments	$87.42M	$214.3M	$214.3M
Other Short-Term Assets	$6.015M	$6.597M	$6.597M
YoY Change	11.66%	19.32%	19.32%
Inventory	$47.73M	$51.48M	$51.48M
Prepaid Expenses
Receivables	$34.31M	$28.07M	$28.07M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$337.3M	$373.6M	$373.6M
YoY Change	-10.64%	-8.82%	-8.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.19M	$15.88M	$21.99M
YoY Change	9.42%	22.46%	8.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.067M	$1.166M	$4.477M
YoY Change	562.73%	647.44%	-86.62%
Total Long-Term Assets	$25.39M	$26.47M	$26.47M
YoY Change	-53.26%	-50.67%	-50.67%
TOTAL ASSETS
Total Short-Term Assets	$337.3M	$373.6M	$373.6M
Total Long-Term Assets	$25.39M	$26.47M	$26.47M
Total Assets	$362.7M	$400.1M	$400.1M
YoY Change	-16.0%	-13.67%	-13.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.988M	$603.0K	$603.0K
YoY Change	-61.39%	-65.8%	-65.8%
Accrued Expenses	$27.96M	$35.58M	$35.58M
YoY Change	-9.2%	-10.11%	-10.11%
Deferred Revenue	$9.038M	$8.662M
YoY Change	32.27%	36.62%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$44.27M	$51.95M	$51.95M
YoY Change	-9.45%	0.49%	0.49%
LONG-TERM LIABILITIES
Long-Term Debt	$96.48M	$96.34M	$96.34M
YoY Change	223.93%	223.69%	223.69%
Other Long-Term Liabilities	$5.631M	$5.840M	$5.840M
YoY Change	-26.05%	-26.32%	-26.32%
Total Long-Term Liabilities	$96.48M	$96.34M	$102.2M
YoY Change	223.93%	223.69%	171.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.27M	$51.95M	$51.95M
Total Long-Term Liabilities	$96.48M	$96.34M	$102.2M
Total Liabilities	$146.4M	$154.1M	$154.1M
YoY Change	69.64%	72.43%	72.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$832.9M	-$789.0M
YoY Change	25.64%	26.04%
Common Stock	$1.049B	$1.036B
YoY Change	4.0%	3.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$216.3M	$246.0M	$246.0M
YoY Change
Total Liabilities & Shareholders Equity	$362.7M	$400.1M	$400.1M
YoY Change	-16.0%	-13.67%	-13.67%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$44.00M	-$41.44M	-$163.0M
YoY Change	19.27%	0.51%	23.51%
Depreciation, Depletion And Amortization	$1.384M	$1.269M	$5.169M
YoY Change	9.67%	-2.08%	0.14%
Cash From Operating Activities	-$44.76M	-$34.51M	-$145.7M
YoY Change	16.75%	5.6%	11.87%
INVESTING ACTIVITIES
Capital Expenditures	$810.0K	$2.109M	$8.325M
YoY Change	-45.2%	-347.83%	167.86%
Acquisitions
YoY Change
Other Investing Activities	$3.453M	-$49.64M	-$57.97M
YoY Change	-110.82%	218.87%	-58.41%
Cash From Investing Activities	$2.643M	-$51.75M	-$66.30M
YoY Change	-107.92%	215.19%	-53.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.277M	65.60M	72.90M
YoY Change	41.74%	6923.55%	-54.48%
NET CHANGE
Cash From Operating Activities	-44.76M	-34.51M	-145.7M
Cash From Investing Activities	2.643M	-51.75M	-66.30M
Cash From Financing Activities	5.277M	65.60M	72.90M
Net Change In Cash	-36.84M	-20.66M	-139.1M
YoY Change	-45.83%	-57.11%	23.53%
FREE CASH FLOW
Cash From Operating Activities	-$44.76M	-$34.51M	-$145.7M
Capital Expenditures	$810.0K	$2.109M	$8.325M
Free Cash Flow	-$45.57M	-$36.62M	-$154.1M
YoY Change	14.45%	15.05%	15.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity Registrant Name EntityRegistrantName	Outset Medical, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001484612
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Entity File Number EntityFileNumber	001-39513
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-0514392
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3052 Orchard Dr.
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Jose
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95134
CY2022	dei	City Area Code CityAreaCode	669
CY2022	dei	Local Phone Number LocalPhoneNumber	231-8200
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	OM
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	709000000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48637059
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	San Francisco, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73222000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	182348000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	214280000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	157140000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28070000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25600000
CY2022Q4	us-gaap	Inventory Net InventoryNet	51476000
CY2021Q4	us-gaap	Inventory Net InventoryNet	39185000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6597000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5529000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	373645000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	409802000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3311000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	33311000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15876000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12964000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6117000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7231000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1166000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	156000
CY2022Q4	us-gaap	Assets Assets	400115000
CY2021Q4	us-gaap	Assets Assets	463464000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	603000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1763000
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	21519000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	24948000
CY2022Q4	om	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	16227000
CY2021Q4	om	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13789000
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	3620000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	3704000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8662000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6340000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1318000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1151000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	51949000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	51695000
CY2022Q4	om	Accrued Interest Noncurrent AccruedInterestNoncurrent	113000
CY2021Q4	om	Accrued Interest Noncurrent AccruedInterestNoncurrent	721000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	151000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	312000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5576000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6893000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	96336000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	29762000
CY2022Q4	us-gaap	Liabilities Liabilities	154125000
CY2021Q4	us-gaap	Liabilities Liabilities	89383000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48465000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48465000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47241000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47241000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1035456000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	48000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	47000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1000212000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-564000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-184000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-788950000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-625994000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	245990000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	374081000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	400115000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	463464000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	115375000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	102602000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49935000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	97542000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	94994000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	62972000
CY2022	us-gaap	Gross Profit GrossProfit	17833000
CY2021	us-gaap	Gross Profit GrossProfit	7608000
CY2020	us-gaap	Gross Profit GrossProfit	-13037000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48855000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36741000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28850000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	89482000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	65070000
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	45068000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40515000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36316000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30512000
CY2022	us-gaap	Operating Expenses OperatingExpenses	178852000
CY2021	us-gaap	Operating Expenses OperatingExpenses	138127000
CY2020	us-gaap	Operating Expenses OperatingExpenses	104430000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-161019000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-130519000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-117467000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3291000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	498000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	526000
CY2022	us-gaap	Interest Expense InterestExpense	3566000
CY2021	us-gaap	Interest Expense InterestExpense	1715000
CY2020	us-gaap	Interest Expense InterestExpense	2891000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1367000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1567000
CY2022	om	Change In Fair Value Of Redeemable Convertible Preferred Stock Warrant Liability ChangeInFairValueOfRedeemableConvertiblePreferredStockWarrantLiability	0
CY2021	om	Change In Fair Value Of Redeemable Convertible Preferred Stock Warrant Liability ChangeInFairValueOfRedeemableConvertiblePreferredStockWarrantLiability	0
CY2020	om	Change In Fair Value Of Redeemable Convertible Preferred Stock Warrant Liability ChangeInFairValueOfRedeemableConvertiblePreferredStockWarrantLiability	93000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-162661000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-121492000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-131736000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	295000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	199000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-162956000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-131935000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-121492000
CY2022	om	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-162956000
CY2021	om	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-131935000
CY2020	om	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-79324000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.38
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.38
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.89
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.89
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.85
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.85
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48161
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48161
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45589
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45589
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16358
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16358
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-162956000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-131935000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-121492000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-380000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-185000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-21000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-163336000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-132120000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-121513000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-372187000
CY2020	om	Deemed Dividend On Settlement Of Accrued Dividend DeemedDividendOnSettlementOfAccruedDividend	42530000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	362000
CY2020	om	Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Shares TemporaryEquityCashExercisesOfRedeemableConvertiblePreferredStockWarrantsShares	1655
CY2020	om	Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Value TemporaryEquityCashExercisesOfRedeemableConvertiblePreferredStockWarrantsValue	4288000
CY2020	om	Conversion Of Redeemable Convertible Preferred Stock Warrants To Common Stock Warrants Value ConversionOfRedeemableConvertiblePreferredStockWarrantsToCommonStockWarrantsValue	1252000
CY2020	om	Temporary Equity Conversion Of Convertible Redeemable Preferred Stock In To Common Stock TemporaryEquityConversionOfConvertibleRedeemablePreferredStockInToCommonStock	456561000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	254805000
CY2020	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	3126000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1195000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21439000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-21000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	328609000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	149085000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7628000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17445000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-185000
CY2022	om	Increase Decrease In Accrued Warranty Liability IncreaseDecreaseInAccruedWarrantyLiability	-83000
CY2021	om	Increase Decrease In Accrued Warranty Liability IncreaseDecreaseInAccruedWarrantyLiability	791000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-112624000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	290614000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-131935000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	374081000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3840000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27203000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-380000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-162956000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	245990000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-162956000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-131935000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-121492000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	27203000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	17445000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	21439000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5169000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5162000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3159000
CY2022	om	Non Cash Lease Expense NonCashLeaseExpense	1114000
CY2021	om	Non Cash Lease Expense NonCashLeaseExpense	1022000
CY2020	om	Non Cash Lease Expense NonCashLeaseExpense	596000
CY2022	om	Non Cash Interest Expense NonCashInterestExpense	381000
CY2021	om	Non Cash Interest Expense NonCashInterestExpense	569000
CY2020	om	Non Cash Interest Expense NonCashInterestExpense	641000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-449000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1972000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-50000
CY2022	om	Provision For Inventories ProvisionForInventories	2610000
CY2021	om	Provision For Inventories ProvisionForInventories	1023000
CY2020	om	Provision For Inventories ProvisionForInventories	534000
CY2022	om	Other Non Cash Items OtherNonCashItems	76000
CY2021	om	Other Non Cash Items OtherNonCashItems	81000
CY2020	om	Other Non Cash Items OtherNonCashItems	340000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1367000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1567000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2506000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	19137000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2566000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14730000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	22042000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16287000
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1215000
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1860000
CY2020	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	6245000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1281000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3066000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	737000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3428000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	8103000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	9889000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1811000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5889000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4798000
CY2020	om	Increase Decrease In Accrued Warranty Liability IncreaseDecreaseInAccruedWarrantyLiability	1211000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2161000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2881000
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2754000
CY2022	om	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1150000
CY2021	om	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-882000
CY2020	om	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	77000
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-721000
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-217000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-145729000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-130264000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-99015000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8325000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3108000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9077000
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	261154000
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	178432000
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	32884000
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	203184000
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	39033000
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	45908000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-66295000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-142507000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3947000
CY2022	om	Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases	8042000
CY2021	om	Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases	11062000
CY2020	om	Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases	1186000
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	96059000
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	29630000
CY2022	om	Repayment Of Term Loan And Extinguishment Costs RepaymentOfTermLoanAndExtinguishmentCosts	31203000
CY2021	om	Repayment Of Term Loan And Extinguishment Costs RepaymentOfTermLoanAndExtinguishmentCosts	0
CY2020	om	Repayment Of Term Loan And Extinguishment Costs RepaymentOfTermLoanAndExtinguishmentCosts	30985000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	149085000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	254805000
CY2022	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	126758000
CY2022	om	Proceeds From Issuance Of Cash Exercise Of Redeemable Convertible Preferred Stock Warrant ProceedsFromIssuanceOfCashExerciseOfRedeemableConvertiblePreferredStockWarrant	0
CY2021	om	Proceeds From Issuance Of Cash Exercise Of Redeemable Convertible Preferred Stock Warrant ProceedsFromIssuanceOfCashExerciseOfRedeemableConvertiblePreferredStockWarrant	0
CY2020	om	Proceeds From Issuance Of Cash Exercise Of Redeemable Convertible Preferred Stock Warrant ProceedsFromIssuanceOfCashExerciseOfRedeemableConvertiblePreferredStockWarrant	4288000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72898000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	160147000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	385682000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	215659000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	328283000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37669000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	76533000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	215659000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	328283000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-139126000
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	385000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	83000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	19000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	3185000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1146000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	3270000
CY2022	om	Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities	1150000
CY2021	om	Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities	882000
CY2020	om	Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities	0
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	167000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	121000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	323000
CY2022	om	Deferred Financing Costs Included In Accrued Expenses DeferredFinancingCostsIncludedInAccruedExpenses	750000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	8849000
CY2022	om	Deemed Dividend On Settlement Of Accrued Dividend DeemedDividendOnSettlementOfAccruedDividend	0
CY2021	om	Deferred Financing Costs Included In Accrued Expenses DeferredFinancingCostsIncludedInAccruedExpenses	0
CY2020	om	Deferred Financing Costs Included In Accrued Expenses DeferredFinancingCostsIncludedInAccruedExpenses	0
CY2022	om	Transfer Of Inventories To Property And Equipment TransferOfInventoriesToPropertyAndEquipment	28000
CY2021	om	Transfer Of Inventories To Property And Equipment TransferOfInventoriesToPropertyAndEquipment	1410000
CY2020	om	Transfer Of Inventories To Property And Equipment TransferOfInventoriesToPropertyAndEquipment	2131000
CY2022	om	Transfer Of Property And Equipment To Inventories TransferOfPropertyAndEquipmentToInventories	199000
CY2021	om	Transfer Of Property And Equipment To Inventories TransferOfPropertyAndEquipmentToInventories	1192000
CY2020	om	Transfer Of Property And Equipment To Inventories TransferOfPropertyAndEquipmentToInventories	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2021	om	Deemed Dividend On Settlement Of Accrued Dividend DeemedDividendOnSettlementOfAccruedDividend	0
CY2020	om	Deemed Dividend On Settlement Of Accrued Dividend DeemedDividendOnSettlementOfAccruedDividend	42530000
CY2022	om	Adjustment To Redemption Value On Redeemable Convertible Preferred Stock AdjustmentToRedemptionValueOnRedeemableConvertiblePreferredStock	0
CY2021	om	Adjustment To Redemption Value On Redeemable Convertible Preferred Stock AdjustmentToRedemptionValueOnRedeemableConvertiblePreferredStock	0
CY2020	om	Adjustment To Redemption Value On Redeemable Convertible Preferred Stock AdjustmentToRedemptionValueOnRedeemableConvertiblePreferredStock	362000
CY2022	om	Conversion Of Redeemable Convertible Preferred Stock In To Common Stock Upon Initial Public Offering ConversionOfRedeemableConvertiblePreferredStockInToCommonStockUponInitialPublicOffering	0
CY2021	om	Conversion Of Redeemable Convertible Preferred Stock In To Common Stock Upon Initial Public Offering ConversionOfRedeemableConvertiblePreferredStockInToCommonStockUponInitialPublicOffering	0
CY2020	om	Conversion Of Redeemable Convertible Preferred Stock In To Common Stock Upon Initial Public Offering ConversionOfRedeemableConvertiblePreferredStockInToCommonStockUponInitialPublicOffering	456561000
CY2022	om	Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability For Conversion Of Seriesa Warrants In To Common Stock Warrants ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityForConversionOfSeriesaWarrantsInToCommonStockWarrants	0
CY2021	om	Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability For Conversion Of Seriesa Warrants In To Common Stock Warrants ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityForConversionOfSeriesaWarrantsInToCommonStockWarrants	0
CY2020	om	Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability For Conversion Of Seriesa Warrants In To Common Stock Warrants ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityForConversionOfSeriesaWarrantsInToCommonStockWarrants	1252000
CY2022	om	Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability To Additional Paid In Capital ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityToAdditionalPaidInCapital	0
CY2021	om	Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability To Additional Paid In Capital ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityToAdditionalPaidInCapital	0
CY2020	om	Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability To Additional Paid In Capital ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityToAdditionalPaidInCapital	3126000
CY2022	us-gaap	Stock Issued1 StockIssued1	0
CY2021	us-gaap	Stock Issued1 StockIssued1	0
CY2020	us-gaap	Stock Issued1 StockIssued1	41763000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-163000000.0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-131900000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-121500000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-789000000.0
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	287500000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3300000
CY2022Q4	om	Cash Cash Equivalents Restricted Cash And Short Term Investments CashCashEquivalentsRestrictedCashAndShortTermInvestments	290800000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, allowance for doubtful accounts, inventory valuation and write-downs, warranty obligations, the fair value of equity awards, the valuation of investments, recoverability of the Company’s net deferred tax assets, and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results may differ from those estimates under different assumptions or conditions and the differences may be material.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">and Other Risks and Uncertainties</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, restricted cash, short-term investments, and accounts receivable. Substantially all the Company’s cash and cash equivalents, restricted cash, and investments are held at one financial institution in the United States that management believes is of high credit quality. Such investments may, at times, exceed federally insured limits or may not be covered by deposit insurance at all. The Company has not experienced any credit losses on its cash and cash equivalents, restricted cash or short-term investments through December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company's largest customer accounted for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of revenues. For the year ended December 31, 2021, </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> customers accounted for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of revenues, respectively. For the year ended December 31, 2020, </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> customers accounted for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of revenues, respectively. Accounts receivable are unsecured; however, the Company does assess the collectability of accounts receivable based on a number of factors, including past transaction history with, and the creditworthiness of, the customer. Accordingly, the Company is exposed to credit risk associated with accounts receivab</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">le. One customer ac</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">counted for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> of accounts receivable as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. One customer accounted for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of accounts receivable as of December 31, 2021. To reduce risk, the Company closely monitors the amounts due from its customers and assesses the financial strength of its customers through a variety of methods that include, but are not limited to, engaging directly with customer operations and leadership personnel, visiting customer locations to observe operating activities, and assessing customer longevity and reputation in the marketplace. As a result, the Company believes that its accounts receivable credit risk exposure is limited. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">A material default in payment or a material reduction in purchases from these or any other large customers could have a material adverse impact on the Company’s financial condition, results of operations, and liquidity.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has a manufacturing facility in Tijuana, Mexico which it operates in collaboration with its outsourced business administration service provider, TACNA. The Company is subject to a number of risks associated with operating its Mexico-based manufacturing facility. The manufacturing operations at the facility may suffer disruptions from global or regional public health crises such as the recent COVID-19 pandemic, natural disasters, cyber security attacks, vandalism, terrorism or other political hostilities. Any such occurrences could negatively impact the Company’s ability to produce its products. The Company is also subject to a variety of foreign laws and regulations, including trade and labor restrictions and laws relating to importation, exportation and taxation of goods, and U.S. laws and regulations relating to foreign operations. In addition, because certain of its Mexico-based manufacturing operations incur costs that are denominated in MXN, the Company is exposed to additional risk of currency fluctuations between USD and MXN, which could increase its product and labor costs, thus reducing its gross profit. To date, foreign currency transaction gains and losses have not been material to the Company’s financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, financial results of the Company were not significantly affected by the COVID-19 pandemic, which continues to have global impact. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the pandemic affects the Company’s future financial results and operations will depend on future developments which continue to evolve and are difficult to predict, including but not limited to any resurgences of the virus including emerging variant strains, actions taken to contain or mitigate its impact, as well as the direct and indirect economic effects of the pandemic and related containment measures.</span></p>
CY2022	us-gaap	Advertising Expense AdvertisingExpense	0
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022	om	Warranty Period WarrantyPeriod	P1Y
CY2022	om	Capitalized Contract Cost Amortization Period Description CapitalizedContractCostAmortizationPeriodDescription	The Company applies the practical expedient to expense the commissions as incurred as the expected amortization period is one year or less.
CY2021	us-gaap	Advertising Expense AdvertisingExpense	0
CY2020	us-gaap	Advertising Expense AdvertisingExpense	0
CY2022	om	Matching Contributions MatchingContributions	1400000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	33311000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76533000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	115375000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	102602000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49935000
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	8800000
CY2022Q4	om	Revenue Performance Obligation1 RevenuePerformanceObligation1	8700000
CY2022Q4	om	Revenue Performance Obligation1 RevenuePerformanceObligation1	100000
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6300000
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3200000
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	900000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	21100000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	100000
CY2022	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2021	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3300000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	33300000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73222000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	182348000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	294972000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3311000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	33311000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	215659000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	328283000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	20623000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	18114000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9086000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	6054000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	21767000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15017000
CY2022Q4	us-gaap	Inventory Net InventoryNet	51476000
CY2021Q4	us-gaap	Inventory Net InventoryNet	39185000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26683000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20618000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10807000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7654000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15876000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12964000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5200000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5200000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3200000
CY2022Q4	om	Accrued Inventory Current AccruedInventoryCurrent	5585000
CY2021Q4	om	Accrued Inventory Current AccruedInventoryCurrent	4808000
CY2022Q4	om	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	908000
CY2021Q4	om	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	574000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1261000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1269000
CY2022Q4	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	1364000
CY2021Q4	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	3121000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7109000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4017000
CY2021Q4	om	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13789000
CY2022Q4	om	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	16227000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	3704000
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2913000
CY2022	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	5748000
CY2021	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	7310000
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	5832000
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	6519000
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	3620000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	3704000
CY2019Q3	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	renewal options at the election of the Company to renew or extend the lease
CY2019Q3	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1759000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1759000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1070000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	329000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	375000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	233000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	170000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	180000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	371000
CY2022	us-gaap	Lease Cost LeaseCost	2258000
CY2021	us-gaap	Lease Cost LeaseCost	2314000
CY2020	us-gaap	Lease Cost LeaseCost	1674000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.087
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.087
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	9068000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	17401000
CY2022	om	Schedule Of Weighted Average Remaining Lease Term And Discount Rate Table Textblock ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextblock	<p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The weighted-average remaining lease term and discount rate were as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:70.308%;"/> <td style="width:1.075%;"/> <td style="width:1.0%;"/> <td style="width:11.66%;"/> <td style="width:1.0%;"/> <td style="width:1.075%;"/> <td style="width:1.0%;"/> <td style="width:11.879999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.3</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.3</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Weighted-average discount rate</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	100568000
CY2022Q4	om	Long Term Debt Future Minimum Payments Due LongTermDebtFutureMinimumPaymentsDue	144428000
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	39678000
CY2022Q4	us-gaap	Debt Current DebtCurrent	4750000
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	100000000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	3664000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	96336000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1856000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1911000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1969000
CY2022Q4	om	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	2523000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8259000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1365000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6894000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1318000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5576000
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	100000000
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	30000000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	3664000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	238000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	96336000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	29762000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	8298000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9093000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3533
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.63
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	35.14
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	790
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.86
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	142
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	31.47
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2602
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.97
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M3D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	42161000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2114
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.58
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M4D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	38984000
CY2022	om	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod	0.50
CY2022	om	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod	0.50
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27203000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17445000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21439000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-153226000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-128400000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-121492000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-9435000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3336000
CY2022	om	Loss Before Provision For Income Taxes LossBeforeProvisionForIncomeTaxes	-162661000
CY2021	om	Loss Before Provision For Income Taxes LossBeforeProvisionForIncomeTaxes	-131736000
CY2020	om	Loss Before Provision For Income Taxes LossBeforeProvisionForIncomeTaxes	-121492000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.042
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.013
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.038
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.261
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.228
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.233
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.014
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.012
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.010
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.081
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.012
CY2022	om	Effective Income Tax Rate Reconciliation Non Deductible Permanent Expense EffectiveIncomeTaxRateReconciliationNonDeductiblePermanentExpense	-0.002
CY2021	om	Effective Income Tax Rate Reconciliation Non Deductible Permanent Expense EffectiveIncomeTaxRateReconciliationNonDeductiblePermanentExpense	-0.001
CY2020	om	Effective Income Tax Rate Reconciliation Non Deductible Permanent Expense EffectiveIncomeTaxRateReconciliationNonDeductiblePermanentExpense	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.007
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.014
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.019
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.082
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.021
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	131705000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	102094000
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	362000
CY2020	om	Deemed Dividend On Settlement Of Accrued Dividend DeemedDividendOnSettlementOfAccruedDividend	42530000
CY2022	om	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-162956000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	14172000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	11767000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	4509000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3573000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2143000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	845000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	4686000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3566000
CY2022Q4	om	Deferred Tax Assets Capitalized Research Costs DeferredTaxAssetsCapitalizedResearchCosts	25730000
CY2021Q4	om	Deferred Tax Assets Capitalized Research Costs DeferredTaxAssetsCapitalizedResearchCosts	19405000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2876000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2236000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	185821000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	143486000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	184298000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	141729000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1523000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1757000
CY2022Q4	om	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	-1523000
CY2021Q4	om	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	-1757000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1523000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1757000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	42600000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30700000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	28400000
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	526800000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2190000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1582000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	37000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	800000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	608000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3027000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2190000
CY2022	us-gaap	Significant Change In Unrecognized Tax Benefits Nature Of Event SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent	The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change within the next twelve months.
CY2021	om	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-131935000
CY2020	om	Net Income Loss Attributable To Common Stockholders Basic And Diluted NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted	-79324000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48161
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48161
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45589
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-162956000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-131935000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-121492000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45589
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16358
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16358
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.38
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.38
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.89
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.89
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.85
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.85
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4395000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4231000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4878000
CY2022	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
om-20221231_cal.xml	Edgar Link	unprocessable
om-20221231_lab.xml	Edgar Link	unprocessable
om-20221231_def.xml	Edgar Link	unprocessable
om-20221231_pre.xml	Edgar Link	unprocessable
0000950170-23-002648-index-headers.html	Edgar Link	pending
0000950170-23-002648-index.html	Edgar Link	pending
0000950170-23-002648.txt	Edgar Link	pending
0000950170-23-002648-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img264633676_0.jpg	Edgar Link	pending
img264633676_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
om-20221231.htm	Edgar Link	pending
om-20221231.xsd	Edgar Link	pending
om-ex23_1.htm	Edgar Link	pending
om-ex31_1.htm	Edgar Link	pending
om-ex31_2.htm	Edgar Link	pending
om-ex32_1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
om-20221231_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OM
Outset Medical, Inc. Stock $om

2023 Q1 Form 10-K Financial Statement

#000095017023002648 Filed on February 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OM Outset Medical, Inc. Stock $om

2023 Q1 Form 10-K Financial Statement

#000095017023002648 Filed on February 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OM
Outset Medical, Inc. Stock $om